Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid outcomes study in primary biliary cholangitis
NL-OMON55722Phase 4Active, not recruiting
- Sponsor
- Intercept Pharmaceuticals, Inc
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Ocaliva with Placebo (2 arms). Primary endpoint: Time to first composite liver-related clinical event. Started Aug 2017; status: active, not recruiting.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NL-OMON55722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55722.